Recently, we observed that the combination of metformin and aspirin dramatically down-regulated the mRNA expression of the CCL2 in treated pancreatic cancer cells (50-fold down-regulation vs. untreated cells), indicating a possibility of the use of metformin and aspirin as adjuvant cancer immunotherapy [149]. The gene discussed is CCL2; the disease is pancreatic neoplasm.